A blood-letting problem

It sometimes happens that protocols designed to help patients turn out to do more harm than good. That apparently was the case in a Phase III trial of Alliance Pharmaceutical Corp.'s Oxygent blood substitute in cardiac bypass surgery patients. The good news for ALLP is that Oxygent itself apparently was not responsible for the higher incidence of stroke in treated patients versus controls. The bad news is that the company is likely to do a new Phase

Read the full 775 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers